STK32B and breast carcinoma: Despite the limited number of patients included in the study, the integrative analysis identified at least five of the putative biomarkers originally developed in breast carcinoma (CBX2, CNTNAP2, S100A8, SCUBE2, and STK32B) that also improve risk assessment for OSCC patients and may play a crucial role in cancer-related processes, e.g. hedgehog signaling, regulation of cell cycle progression, cell proliferation, metastasis.